Abiraterone and degarelix are drugs that are each approved for the treatment of advanced prostate cancer. Degarelix lowers the levels of cancer-fueling testosterone in the body. Abiraterone, which is given with prednisone, works by blocking the production of testosterone by inhibiting an enzyme called CYP17. In this study, researchers want to evaluate the effectiveness of these two drugs used alone and in combination in men with an earlier stage of prostate cancer: disease recurrence which is evident only by a rising PSA level after prostate cancer surgery, before the development of metastatic disease is visible on scans.
In this study, patients will be randomly assigned to receive abiraterone and prednisone; abiraterone, prednisone, and degarelix; or degarelix alone. Abiraterone and prednisone are taken orally (by mouth), while degarelix is given as an injection.